EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Soluble E-Cadherin as a New Prognostic Biomarker Able to Predict Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma

Paola Carolina Rabesquini Marcelino da Silva, Igor Cerejo Tavares da Silva de Almeida iD, Joaquim Gasparini Dos Santos, Leonardo Jun Otuyama, Cadiele Oliana Reichert, Hebert Fabrício Culler, Nélio Cézar de Aquino, Lilian de Souza França, Sheila Aparecida Coelho da Siqueira, Renata de Oliveira Costa, Vanderson Rocha, Sérgio Paulo Bydlowski iD und 3 weitere

Biomolecules · 24.04.2026 · 16 (5) · 637

DOI: 10.3390/biom16050637 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, online erschienen am 24.04.2026. Verfasst von Paola Carolina Rabesquini Marcelino da Silva und 14 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Immuno-Onco-Hematology (LIM-31), Faculty of Medicine, University of Sao P…. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Cadherins, Biomarkers, Tumor, Antigens, CD. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PROEX—Programa de pós-graduação em Ciências Médicas da Faculdade de Medicina da Universidade de São Paulo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, constituting an important public health problem. Although curable, it presents a widely variable prognosis. The main tool used for prognostic stratification in DLBCL is the International Prognostic Index (IPI), which does not consider crucial biological variables for understanding its prognostic heterogeneity. Cell adhesion molecules (CAMs) play a central role in cancer biology and can be evaluated in affected tissues or in plasma, in soluble forms (sCAMs). CAMs promote proliferation, survival, and dissemination of malignant cells. Although extensively studied in solid tumors, their role remains unclear in hematological malignancies, particularly in DLBCL.

Methods

This is a prospective and longitudinal study involving 87 newly diagnosed DLBCL (ND-DLBCL) patients aiming to quantify plasma levels of sCAMs (sICAM-1, sVCAM-1, sP-selectin, and sE-cadherin) at diagnosis and assessing its potential prognostic impact, as well as establishing clinical-biological associations.

Results

Plasma quantification of sICAM-1, sVCAM-1, and sP-selectin did not present prognostic impact in DLBCL. However, continuous increases in sE-cadherin levels, as well as sE-cadherin ≥ 126.55 ng/mL were associated with lower response rates to R-CHOP regimen, higher frequency of recurrence following first-line therapy, and shortened survival. Additionally, sE-cadherin concentration ≥ 126.55 ng/mL was an independent predictor related to decreased overall survival. Conclusion: sE-cadherin measured at diagnosis has emerged as a new prognostic biomarker able to predict response, relapse and survival in ND-DLBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseCadherinsBiomarkers, TumorAntigens, CDHumansFemaleMalePrognosisMiddle AgedAgedAntineoplastic Combined Chemotherapy ProtocolsVincristineAdultPrednisoneCyclophosphamideProspective StudiesDoxorubicinIntercellular Adhesion Molecule-1Longitudinal StudiesRituximabVascular Cell Adhesion Molecule-1Aged, 80 and overP-Selectin

Stichwörter der Autor:innen

cancer biomarkerscell adhesion moleculesdiffuse large B-cell lymphomaprognosissE-cadherinsICAM-1sP-selectinsVCAM-1

Substanzen

CadherinsBiomarkers, TumorVincristinePrednisoneCyclophosphamideDoxorubicinIntercellular Adhesion Molecule-1RituximabVascular Cell Adhesion Molecule-1Antigens, CD

Autor:innen und Institutionen

  • Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Immuno-Onco-Hematology (LIM-31), Faculty of Medicine, University of Sao Paulo, Sao Paulo 05430-000, Brazil.
  • Department of Hematology, Hemotherapy & Cell Therapy, Faculty of Medicine, University of Sao Paulo, Sao Paulo 05430-000, Brazil.
  • Department of Pathology, Faculty of Medicine, University of Sao Paulo, Sao Paulo 05430-000, Brazil.
  • Department of Hematology, Faculdade de Ciências Médicas de Santos, Fundação Lusíada, Santos 11050-071, Brazil.
  • Department of Hematology & Oncology, Hospital Alemão Oswaldo Cruz, Sao Paulo 01323-020, Brazil.
  • Pró-Sangue Foundation, Blood Bank of Sao Paulo, Sao Paulo 05430-000, Brazil.

ORCID-Profile: Igor Cerejo Tavares da Silva de Almeida, Sérgio Paulo Bydlowski, Débora Levy, Juliana Pereira, Luís Alberto de Pádua Covas Lage

Förderung

  • PROEX—Programa de pós-graduação em Ciências Médicas da Faculdade de Medicina da Universidade de São Paulo

Zitieren

APA

da Silva, P. C. R. M., de Almeida, I. C. T. D. S., Dos Santos, J. G., Otuyama, L. J., Reichert, C. O., Culler, H. F., de Aquino, N. C., França, L. S., da Siqueira, S. A. C., Costa, R. O., Rocha, V., Bydlowski, S. P., Levy, D., Pereira, J., & Lage, L. A. P. C. (2026). Soluble E-Cadherin as a New Prognostic Biomarker Able to Predict Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma. Biomolecules, 16(5), 637. https://doi.org/10.3390/biom16050637

Vancouver

da Silva PCRM, de Almeida ICTDS, Dos Santos JG, Otuyama LJ, Reichert CO, Culler HF, et al. Soluble E-Cadherin as a New Prognostic Biomarker Able to Predict Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma. Biomolecules. 2026;16(5):637. doi:10.3390/biom16050637

BibTeX
@article{daSilva2026,
  author = {da Silva, Paola Carolina Rabesquini Marcelino and de Almeida, Igor Cerejo Tavares da Silva and Dos Santos, Joaquim Gasparini and Otuyama, Leonardo Jun and Reichert, Cadiele Oliana and Culler, Hebert Fabrício and de Aquino, Nélio Cézar and França, Lilian de Souza and da Siqueira, Sheila Aparecida Coelho and Costa, Renata de Oliveira and Rocha, Vanderson and Bydlowski, Sérgio Paulo and Levy, Débora and Pereira, Juliana and Lage, Luís Alberto de Pádua Covas},
  title = {Soluble E-Cadherin as a New Prognostic Biomarker Able to Predict Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma},
  journal = {Biomolecules},
  year = {2026},
  volume = {16},
  number = {5},
  pages = {637},
  doi = {10.3390/biom16050637}
}
Kostenlos starten →